Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR), a biopharmaceutical company with a market capitalization of $2.68 billion ...

Merck and Eisai reported new data for a drug regimen of Keytruda and Lenvima. Elsewhere, AstraZeneca expanded in Canada and ...

The Trump administration is bringing new instability to a sector already grappling with a shaky market as well as threats ...

This new tool, known as minimal, versatile genetic perturbation technology (mvGPT), combines the powers of gene editing, ...

NEW YORK, January 16, 2025--PESG Releases a Market Update - Silexion Therapeutics (NASDAQ: SLXN), a clinical-stage biotech advancing RNA interference (RNAi) therapies for KRAS-driven cancers ...

In this review of RNA therapies, we paint an overview of what’s going on in a field that is addressing a number of diseases.

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it will host a webcast and conference call on February 10, 2025, at 4:30 p.m. ET to discuss its financial results for the fiscal ...

With its International Headquarters in Zug, Switzerland, Alnylam has become a key part of the Swiss biotech environment.

The FDA has accepted for review the New Drug Application for plozasiran for the treatment for familial chylomicronemia syndrome.

Benitec has a market cap of $250mn, $67.8mn in cash, and a cash runway of over 10 quarters, but faces risks due to its small ...

This is a useful study that seeks to address the role of the TET family of DNA demethylation enzymes in pancreatic beta cell senescence in the context of type 2 diabetes (T2DM). Although the concepts ...

Functional genomics can help deconvolute the link between genotype and phenotype in disease, revealing new drug targets and ...